دورية أكاديمية
Response to anti-HER2 neoadjuvant chemotherapy in HER2-positive invasive breast cancers with different HER2 FISH patterns.
| العنوان: | Response to anti-HER2 neoadjuvant chemotherapy in HER2-positive invasive breast cancers with different HER2 FISH patterns. |
|---|---|
| المؤلفون: | Lv H; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China., Bai QM; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China., Li M; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China., Cai MY; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China., Zhou SL; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China., Liu Y; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China., Wang ZH; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China., Shui RH; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China., Lu HF; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China., Xu XL; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China., Yu BH; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China., Tu XY; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China., Bi R; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China., Cheng YF; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China., Zhou XY; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China., Shao ZM; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China., Yang WT; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China yangwt2000@163.com.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China. |
| المصدر: | Journal of clinical pathology [J Clin Pathol] 2024 Feb 12. Date of Electronic Publication: 2024 Feb 12. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: BMJ Pub. Group Country of Publication: England NLM ID: 0376601 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1472-4146 (Electronic) Linking ISSN: 00219746 NLM ISO Abbreviation: J Clin Pathol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : BMJ Pub. Group Original Publication: London : British Medical Association |
| مستخلص: | Aims: Human epidermal growth factor receptor 2 (HER2)-positive patients with breast cancer may have different HER2/CEP17 ratios and HER2 copy numbers, with inconsistent responses to anti-HER2 neoadjuvant chemotherapy (NACT). Our study aimed to explore the relationship between different HER2 fluorescence in situ hybridisation (FISH) patterns in HER2-positive patients with breast cancer and responses to anti-HER2 NACT. Methods: 527 patients with HER2-positive invasive breast cancer who received anti-HER2 NACT from 2015 to 2022 were included and divided into three groups by FISH results, namely group A: HER2/CEP17<2.0 and HER2 copy numbers ≥6.0, HER2 immunohistochemistry 2/3+; group B: HER2/CEP17≥2.0 and HER2 copy numbers ≥4.0 and <6.0; group C: HER2/CEP17≥2.0 and HER2 copy numbers ≥6.0. We compared clinicopathological characteristics and pathological complete response (pCR) rates of different groups. Results: According to HER2 FISH results, 12 patients (2.3%, 12/527) were in group A, 40 (7.6%, 40/527) were in group B and 475 (90.1%, 475/527) were in group C. The pCR rate was the lowest in group B (5.0%), while the pCR rates in group A and group C were 33.3% and 44.4%, respectively (p Conclusions: Patients with HER2/CEP17≥2.0 and HER2 copy numbers ≥4.0 and <6.0 do not benefit to the same extent from current anti-HER2 therapies as FISH-positive patients with other patterns. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.) |
| فهرسة مساهمة: | Keywords: BREAST; CARCINOMA; Pathology, Molecular |
| تواريخ الأحداث: | Date Created: 20240212 Latest Revision: 20240212 |
| رمز التحديث: | 20240213 |
| DOI: | 10.1136/jcp-2023-209069 |
| PMID: | 38346865 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1472-4146 |
|---|---|
| DOI: | 10.1136/jcp-2023-209069 |